Esperion acquires Corstasis Therapeutics
Esperion agreed to acquire Corstasis Therapeutics. Reported deal value: $75M. Status: Pending. Sector: biopharmaceutical. Target headquarters context: Henderson, Nevada, United States.
This page summarizes publicly available information about the transaction as of 2026-03-03. Figures and status may change as filings and press coverage update.
Agreement and Plan of Merger On March 2, 2026, Esperion Therapeutics , Inc. entered into an Agreement and Plan of Merger with Corstasis Therapeutics Inc. , a Delaware corporation , and Cirrus Transaction Subsidiary, Inc., a Delaware corporation and wholly-owned subsidiary of the Company
Deal timeline
This transaction is classified in biopharmaceutical with a reported deal value of $75M. Figures and status may change as sources update.